These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35092319)

  • 21. The Evolving Role of Liver Biopsy in Non-alcoholic Fatty Liver Disease.
    Arab JP; Barrera F; Arrese M
    Ann Hepatol; 2018 Oct; 17(6):899-902. PubMed ID: 30600304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis.
    Sourianarayanane A; Talluri J; Humar A; McCullough AJ
    Eur J Gastroenterol Hepatol; 2017 May; 29(5):516-523. PubMed ID: 28079667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems.
    Schmitz SM; Kroh A; Ulmer TF; Andruszkow J; Luedde T; Brozat JF; Neumann UP; Alizai PH
    BMC Gastroenterol; 2020 Aug; 20(1):254. PubMed ID: 32758151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.
    Berardo C; Di Pasqua LG; Cagna M; Richelmi P; Vairetti M; Ferrigno A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies.
    Lin TY; Yeh ML; Huang CF; Huang CI; Dai CY; Hsieh MH; Chen SC; Huang JF; Yu ML; Chuang WL
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):224-229. PubMed ID: 30308578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
    Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
    J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EVALUATION OF PROGRESSION OF HEPATIC FIBROSIS IN A GROUP OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANIED FOR 10 YEARS.
    Castro PCS; Alberton HCP; Pedroso MLA; Morsoletto DBG; Pissaia Junior A; Ivantes CAP
    Arq Gastroenterol; 2019; 56(3):256-260. PubMed ID: 31633721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward.
    Li W
    J Hepatol; 2020 Aug; 73(2):465-466. PubMed ID: 32416974
    [No Abstract]   [Full Text] [Related]  

  • 29. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H; Dufour JF
    Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Machanism and intervention of nonalcoholic steatohepatitis-associated fibrosis].
    Wu J
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):415-419. PubMed ID: 31357755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease.
    Mosca A; Comparcola D; Romito I; Mantovani A; Nobili V; Byrne CD; Alisi A; Targher G
    Liver Int; 2019 Dec; 39(12):2317-2329. PubMed ID: 31436362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [PROGNOSIS ASSESSMENT OF THE COMBINED COURSE OF STABLE CORONARY HEART DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS AFTER REVASCULARIZATION INTERVENTIONS].
    Vakalyuk I; Virstyuk N; Vakaliuk I
    Georgian Med News; 2020 Nov; (308):47-52. PubMed ID: 33395640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis.
    Kang SH; Yoon EL
    Gut Liver; 2023 Jan; 17(1):8-9. PubMed ID: 36636885
    [No Abstract]   [Full Text] [Related]  

  • 34. Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.
    Park H; Yoon EL; Cho S; Jun DW; Nah EH
    Gut; 2022 May; 71(5):1035-1036. PubMed ID: 34127524
    [No Abstract]   [Full Text] [Related]  

  • 35. FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage.
    Lombardi R; Petta S; Pisano G; Dongiovanni P; Rinaldi L; Adinolfi LE; Acierno C; Valenti L; Boemi R; Spatola F; Craxì A; Fargion S; Fracanzani AL
    Clin Gastroenterol Hepatol; 2020 Feb; 18(2):517-519. PubMed ID: 30528844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications.
    Angulo P; Machado MV; Diehl AM
    Semin Liver Dis; 2015 May; 35(2):132-45. PubMed ID: 25974899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of bariatric surgery in the management of nonalcoholic steatohepatitis.
    Seymour KA; Abdelmalek MF
    Curr Opin Gastroenterol; 2021 May; 37(3):208-215. PubMed ID: 33769376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Weight Changes With Changes in Histological Features and Blood Markers in Nonalcoholic Steatohepatitis.
    Koutoukidis DA; Jebb SA; Tomlinson JW; Cobbold JF; Aveyard P
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e538-e547. PubMed ID: 33813074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study.
    Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R
    PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.